Abstract: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogues exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.
Abstract: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.
Type:
Application
Filed:
September 13, 2013
Publication date:
September 11, 2014
Applicant:
Paion Deutschland GmbH
Inventors:
Karl-Uwe Petersen, Michael Ernest Nesheim, Jonathan Herbert Foley
Abstract: The invention relates to a protein or peptide consisting of a kringle protein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N-terminal domain of the NMDA receptor subunit NR1 (anti-NR1 antibody), whereas binding of the antibody or the fragment thereof prevents the cleavage of the extracellular domain of the NR1 subunit, or the fragment and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates further to a pharmaceutical composition containing said kringle protein or peptide or anti-NR1 antibody.
Type:
Application
Filed:
February 29, 2012
Publication date:
March 7, 2013
Applicants:
INSERM, PAION DEUTSCHLAND GMBH
Inventors:
Denis Vivien, Carine Ali, Richard Macrez, Karl-Uwe Petersen
Abstract: The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulopathy with hyperfibrinolysis, such as haemophilia disorders. These thrombomodulin analogs exhibit at therapeutically effective dosages an antifibrinolytic effect. Novel protein modifications together with methods for their identification are disclosed.
Type:
Application
Filed:
June 12, 2009
Publication date:
October 25, 2012
Applicant:
PAION Deutschland GmbH
Inventors:
Karl-Uwe Petersen, Michael Ernest Nesheim, Daniel Nesheim, Jonathan Herbert Foley
Abstract: The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans.
Type:
Grant
Filed:
June 27, 2008
Date of Patent:
December 6, 2011
Assignee:
Paion Deutschland GmbH
Inventors:
Robert Medcalf, Mariola Söhngen, Wolfgang Söhngen, Wolf-Dieter Schleuning
Abstract: The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.